Ingelvac MycoFLEX®
For the active immunisation of pigs from the age of three weeks to reduce lung lesions following infections with Mycoplasma hyopneumoniae.
Search
Informed decision and safe use of medications
It's about time we better understood the burden of serious mental illness
Launch of first veterinary vaccines produced in China
Swine vaccine Ingelvac PRRS MLV, produced by Boheringer Ingelheim veterinary vaccine manufacturing plant in Taizhou is now officially supplied to the China market.
Investment of 65 million euro in avian vaccines in France
Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines
Inauguration of new integrated Asian Veterinary R&D Center in China
Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
Launch of Frontline flagship store on Tmall
Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.
Building blocks of our future
Our global investment projects are the building blocks for improved healthcare and sustainability
Test Teaser Card Download to show up at the end of an article
Test
Corporate Profile
Corporate Profile
Yanina Donatini
Yanina Donatini, Head of ITM&S Content Production, jumped at the chance to fulfill her dreams within the Information Technology division at Boehringer Ingelheim.
Fremont
Upstream process development in a high throughput automated bioreactor system.
Social Media Data Privacy and Cookies Statement
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Careers beyond borders
Careers beyond borders
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Transforming Science Day
How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Moving to Germany
We started in Germany, but we have offices all over the world.
Boehringer unveils first global sustainability publication
Boehringer Ingelheim unveils its first global sustainability publication ‘Imagine’
Our Biotech Story | Bioxcellence | Boehringer Ingelheim
Discover our pioneering history & leadership in biotechnology, driving innovation in biopharmaceutical manufacturing & breakthrough therapies.
Announcement for Imagine - our new sustainability story hub
Discover Imagine, our sustainability story hub, showcasing how we drive health equity and advance sustainable healthcare solutions for a better future
Family owned
Did you know that Boehringer is still family-owned? Read this article to learn more about our culture. Check out our Careers Page for more talent insights!